文献速递自身炎症与 IgG4 相关病

重组IL-1受体拮抗剂作为一线单药治疗新发全身型JIA的达标治疗:五年随访结果

Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
PubMed 文献 · Arthritis Rheumatol · 2019-05-25

这项单中心前瞻性研究评估了以重组白细胞介素-1受体拮抗剂(rIL-1Ra;阿那白滞素)作为一线单药、按达标治疗策略治疗新发全身型幼年特发性关节炎(JIA)的疗效。

要点

  • rIL-1Ra一线单药达标治疗可快速诱导全身型JIA无活动性疾病。
  • 5年随访中多数患者可停用药物维持无活动性疾病且损害率低。
  • 基线中性粒细胞高和1个月完全应答与1年无活动性疾病高度相关。

核心结论

  • 以rIL-1Ra一线短程单药开始的达标治疗策略能高效诱导并维持全身型JIA无活动性疾病,并预防疾病及糖皮质激素相关损害。

研究设计与样本

  • 单中心前瞻性研究纳入新发全身型JIA且非甾体抗炎药反应不佳的患者,接受rIL-1Ra单药达标治疗,中位随访5.8年。

主要发现

  • 5年随访时96%无活动性疾病、75%无药无活动性疾病,关节或关节外损害<5%,仅33%接受糖皮质激素。
  • 基线中性粒细胞计数高和rIL-1Ra治疗1个月后完全应答与1年时无活动性疾病高度相关。
  • rIL-1Ra对起病时无关节炎的全身型JIA患者同样有效。

关键数值与推荐

  • 对2 mg/kg rIL-1Ra应答不完全者后续接受4 mg/kg rIL-1Ra或加用泼尼松龙,或换用替代治疗。
  • 达无活动性疾病者rIL-1Ra在3个月后逐渐减量并随后停药。

临床怎么用

  • 对新发全身型JIA可考虑以rIL-1Ra一线单药按达标治疗策略起始,以快速诱导无活动性疾病并减少糖皮质激素暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic juvenile idiopathic arthritis (JIA) is a multifactorial autoinflammatory disease with a historically poor prognosis. With current treatment regimens, approximately half of patients still experience active disease after 1 year of therapy. This study was undertaken to evaluate a treat-to-target approach using recombinant interleukin-1 receptor antagonist (rIL-1Ra; anakinra) as first-line monotherapy to achieve early inactive disease and prevent damage. METHODS: In this single-center, prospective study, patients with new-onset systemic JIA with an unsatisfactory response to nonsteroidal antiinflammatory drugs received rIL-1Ra monotherapy according to a treat-to-target strategy. Patients with an incomplete response to 2 mg/kg rIL-1Ra subsequently received 4 mg/kg rIL-1Ra or additional prednisolone, or switched to alternative therapy. For patients in whom inactive disease was achieved, rIL-1Ra was tapered after 3 months and subsequently stopped. RESULTS: Forty-two patients, including 12 who had no arthritis at disease onset, were followed up for a median of 5.8 years. The median time to achieve inactive disease was 33 days. At 1 year, 76% had inactive disease, and 52% had inactive disease while not receiving medication. High neutrophil counts at baseline and a complete response after 1 month of rIL-1Ra were highly associated with inactive disease at 1 year. After 5 years of follow-up, 96% of the patients included had inactive disease, and 75% had inactive disease while not receiving medication. Articular or extraarticular damage was reported in <5%, and only 33% of the patients received glucocorticoids. Treatment with rIL-1Ra was equally effective in systemic JIA patients without arthritis at disease onset. CONCLUSION: Treatment to target, starting with first-line, short-course monotherapy with rIL-1Ra, is a highly efficacious strategy to induce and sustain inactive disease and to prevent disease- and glucocorticoid-related damage in systemic JIA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol. 2019. PMID: 30848528. doi:10.1002/art.40865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。